-
Product Insights
Innovations in Women’s Health – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in Women's Health - Global Pipeline Summary" provides comprehensive information about the Women's Health pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Women's Health report provides key information and data related to: Extensive coverage of the Women's Health under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories,...
-
Product Insights
NewAspira Womens Health Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Aspira Womens Health Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Aspira Womens Health Inc (Aspira), formerly Vermillion Inc, is a medical device company. It offers diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, is a simple blood test. Its other products includes OVERA, a second-generation biomarker panel intended to maintain OVA1’s high...
-
Sector Analysis
NewBusiness of the National Women’s Soccer League (NWSL) 2024 – Property Profile, Sponsorship and Media Landscape
National Women’s Soccer League (NWSL) 2024 Report Overview The estimated sponsorship revenue of the National Women’s Soccer League (NWSL) is $25.5 million for the 2024 season through 11 active sponsorship deals. A major shift in the media rights landscape has begun in 2024, with four major partners agreeing to terms for exclusive coverage in the US. These deals are effective between the 2024 and 2027 seasons. The National Women’s Soccer League (NWSL) 2024 report provides an overview of the National...
-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Ovarian Cancer Drug Details: Palbociclib (Ibrance, Agatha) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Cervical Cancer Drug Details: Palbociclib (Ibrance, Agatha) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Hepatocellular Carcinoma Drug Details: Palbociclib (Ibrance, Agatha) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Metastatic Pancreatic Cancer Drug Details: Palbociclib (Ibrance, Agatha)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Renal Cell Carcinoma Drug Details: Palbociclib (Ibrance, Agatha)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Papillary Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Papillary Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Papillary Renal Cell Carcinoma Drug Details: Palbociclib...